Skip to main content

Table 1 Risk stratification for metastatic seminoma and non-seminoma

From: Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report

Risk stratification

Seminoma

Non-seminoma

Good

Any hCG

AFP < 1000 ng/ml

hCG < 5000 mU/ml

LDH < 1.5 × ULN

Any LDH

Non-pulmonary visceral metastases absent

Gonadal or retroperitoneal primary tumor

Intermediate

Any hCG

AFP 1000–10,000 ng/ml

Any LDH

hCG 5000–50,000 mU/ml

LDH 1.5–10 × ULN

Any primary site

Non-pulmonary visceral metastases absent

Non-pulmonary visceral metastases absent

Gonadal or retroperitoneal primary tumor

Poor

None

AFP > 10,000 ng/ml

hCG > 50,000 mU/ml

LDH > 10 × ULN

Mediastinal primary site

Non-pulmonary visceral metastases present

  1. AFP alpha fetoprotein, hCG human chorionic gonadotrophin, LDH lactate dehydrogenase, ULN upper limit of normal (adopted from the International Germ Cell Cancer Collaborative Group risk classification for metastatic disease [4])